Pure Biologics

Pure Biologics SA is one of the largest Polish biotech companies. Founded in 2010, it is listed on the Warsaw Stock Exchange.

Pure Biologics’ major activity focuses on bispecific, fusion antibodies and aptamers to be developed into therapeutics in immunooncology and in the treatment of neurological diseases.
To this end, Pure Biologics has created highly efficient platforms to generate specific antibodies and modified aptamers, supported by state-of-the-art assays and analytics.

Pure Biologics utilizes its broad experience in antibodies, aptamers, cell and molecular biology, protein and antigen expression and purification, assay development and ligand-binding analysis, offering complex solutions as a contract research organization and service provider, but primarily as a professional consultant and R&D partner.

Pure Biologics aims to out-license its early-stage assets and to connect with partners in need of complex biotechnological solutions.